Rho Partners with TRI


Applied Clinical Trials

Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced that it has partnered with Triumph Research Intelligence (TRI), a global company focused in centralized and risk-based quality management (RBQM) technology.

“We’re very excited about this collaboration with TRI, as it will enable us to deliver an even better service to our Sponsors,” said Matthew Healy, Vice President, Clinical Operations at Rho. “Having a fully validated tool that delivers the entire end-to-end RBQM processes is a key differentiator for us. It means that we can be confident in identifying and documenting potential study risks right from the start, then using the tools we can spot and manage emerging trends, acting much more quickly to target our onsite monitoring activities and focus our efforts on those areas that will improve data quality and better ensure patient safety.”

TRI’s RBQM technology platform optimizes trial quality by improving data reliability, patient safety and operational efficiency. Regulatory guidance requiring the adoption of RBQM has led to a rapid increase in demand for centralized and risk-based monitoring solutions from CROs and Sponsors.

“We’re delighted to be partnering with Rho as they are one of the leading CRO’s with a global reputation for excellence,” said Duncan Hall, CEO and Founder of TRI. “In a world of big data, it’s still people that have to make the decisions. Our RBQM technology platform, OPRA, will enable Rho and their Sponsors to make better informed decisions faster, leading to better quality trials and improved patient safety.”

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
Related Content
© 2024 MJH Life Sciences

All rights reserved.